New York, New York--(Newsfile Corp. - February 13, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Klarna Group plc (NYSE: KLAR) pursuant and/or traceable to the registration statement and related prospectus (collectively, the "Registration Statement") issued in connection with Klarna's September 2025 initial public offering (the "IPO"), of the important February 20, 2026 lead plaintiff deadline in the securities class action first filed by the Firm.SO WH ...

Core Viewpoint - A class action lawsuit has been filed against Klarna Group plc on behalf of investors who acquired Klarna securities during the specified class period, alleging omissions in the IPO registration statement regarding potential increases in loss reserves [1][3]. Group 1: Lawsuit Details - The lawsuit claims that Klarna's IPO Registration Statement failed to disclose critical information, particularly the understatement of potential increases in loss reserves post-IPO [3]. - The complaint indicates that starting from November 18, 2025, reports emerged about Klarna increasing its provisions for credit losses due to rising defaults among its customers [3]. Group 2: Financial Performance - As of the lawsuit filing, Klarna shares were trading at $31.31, which is significantly lower than the IPO price of $40 [4]. Group 3: Company Overview - Klarna, headquartered in Stockholm, Sweden, is a financial technology company that facilitates loans for small purchases, including food delivery services [2].

Core Insights - Buy Now, Pay Later (BNPL) services like Affirm and Klarna are increasingly popular among consumers, particularly younger demographics, allowing them to make purchases in smaller, often interest-free payments [3][10] - Analysts are divided on the investment potential of Affirm versus Klarna, with some viewing Affirm as a stronger buy due to its lower fees and established profitability [14][18] Industry Overview - The BNPL market is growing as consumers seek flexible payment options, with services allowing payments to be split into smaller amounts without interest, appealing to a wide range of consumers [6][9] - The Federal Reserve indicates that credit card debt in the U.S. has reached $1.28 trillion, highlighting a shift towards alternative payment methods like BNPL [5] Consumer Behavior - Approximately 19% of individuals aged 18 to 29 and 30 to 44 have utilized BNPL services, with late payment rates being notably higher among younger users [10][11] - The financial stability of consumers using BNPL is questioned, as a significant percentage of users report making late payments, indicating potential budgeting risks [11][13] Company Performance - Affirm's CEO reported that a majority of their users are financially stable, with 72% of stable users and 89% of fragile users making multiple BNPL purchases in a year [13] - Affirm is currently priced at $54.26, down 27% year-to-date, while Klarna is trading at $18.34, having experienced a 36% decline year-to-date [17][20] Investment Analysis - Analysts have mixed views on Affirm and Klarna, with some recommending Affirm as a buy due to its profitability and lower fees, while others express caution regarding Klarna's lack of profitability and potential risks [14][19] - Merc Research has a contrarian view on Affirm, suggesting a strong sell position due to anticipated challenges in the UK market and competition in the checkout space [16] Market Dynamics - Both Affirm and Klarna have established relationships with retailers, with Klarna offering cash back for certain merchants, while Affirm has discontinued its cash back rewards program [21]

Core Viewpoint - A class action lawsuit has been filed against uniQure N.V. for securities law violations, specifically for making false and misleading statements regarding its FDA approval process and study design [1] Group 1: Lawsuit Details - The lawsuit pertains to violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 [1] - The class period for the lawsuit is from September 24, 2025, to October 31, 2025, with a deadline for lead plaintiff appointments set for April 13, 2026 [1] - The complaint alleges that uniQure's public statements were materially misleading, particularly regarding the likelihood of delays in its Biologics License Application (BLA) with the FDA due to the need for additional studies [1] Group 2: Company Background - uniQure N.V. is a biotechnology company that focuses on gene therapies [1] - The company is listed on NASDAQ under the ticker symbol QURE [1] - The DJS Law Group, which is handling the lawsuit, specializes in securities class actions and corporate governance litigation [1]

Core Viewpoint - Kyndryl Holdings, Inc. is under investigation for potential violations of securities laws, particularly concerning misleading statements and undisclosed information that may have affected investors [1] Investigation Details - The investigation is prompted by a report from Barron's indicating that Kyndryl's shares dropped significantly after the announcement of the departure of its chief financial officer amid an accounting review and weaker-than-expected earnings [1] - On February 9, 2026, Kyndryl's shares fell by more than 55% during morning trading following these revelations [1] Legal Representation - The DJS Law Group is leading the investigation and aims to enhance investor returns through legal advocacy, focusing on securities class actions and corporate governance litigation [1] - The firm represents large hedge funds and alternative asset managers, emphasizing the value of litigation claims as significant assets [1]

SAN FRANCISCO, Feb. 12, 2026 (GLOBE NEWSWIRE) -- National shareholder rights law firm Hagens Berman is notifying investors in Klarna Group plc (NYSE: KLAR) of the upcoming February 20, 2026, lead plaintiff deadline in a pending securities class action. The firm is actively investigating the lawsuit’s claims of alleged misstatements in Klarna’s September 2025 Initial Public Offering (IPO) documents. CLICK HERE TO SUBMIT YOUR KLARNA LOSSES Investors who purchased Klarna (KLAR) shares pursuant to the company’s ...

NEW YORK, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Klarna Group plc ("Klarna Group plc" or the "Company") (NYSE: KLAR) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Klarna Group plc investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of persons who purchased or otherwise acquired Klarna securities pursuant and/or traceable to the registration statement and related prospect ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Klarna Group plc about the upcoming lead plaintiff deadline for a class action lawsuit related to Klarna's September 2025 IPO [1]. Group 1: Class Action Details - Investors who purchased Klarna securities may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by February 20, 2026 [3]. - Investors can join the class action by visiting the provided link or contacting the law firm directly for more information [6]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting their own success in this area [4]. - The firm has achieved significant settlements for investors, including over $438 million in 2019 alone, and has been recognized for its performance in securities class action settlements [4]. Group 3: Case Allegations - The lawsuit claims that the Registration Statement issued during the IPO contained false or misleading statements, particularly regarding the risk of Klarna's loss reserves increasing shortly after the IPO [5]. - It is alleged that the defendants either knew or should have known about the risks associated with Klarna's buy now, pay later loans, leading to misleading public statements [5].

Core Viewpoint - A class action lawsuit has been filed against Beyond Meat, Inc. and certain officers for alleged violations of federal securities laws during the Class Period from February 27, 2025, to November 11, 2025, seeking damages for misleading statements regarding the company's financial health and operations [1]. Group 1: Lawsuit Details - The class action was filed in the United States District Court for the Central District of California, seeking to recover damages for all persons and entities that purchased Beyond Meat securities during the specified Class Period [1]. - Investors have until March 24, 2026, to request appointment as Lead Plaintiff for the class [1]. Group 2: Company Background - Beyond Meat operates in the food industry, focusing on developing, manufacturing, marketing, and selling plant-based meat products under the "Beyond" brand in the U.S. and internationally [1]. - The company has been facing challenges such as shrinking demand, increasing debt, and losses, with a primary goal of achieving positive EBITDA by the end of 2026 [1]. Group 3: Allegations and Financial Impact - The complaint alleges that Defendants made materially false and misleading statements about the company's business and operations, failing to disclose significant asset impairment charges that were likely to occur [1]. - On October 24, 2025, Beyond Meat reported an expected non-cash impairment charge for Q3 2025, leading to a stock price drop of 23.06% [1]. - Subsequent announcements regarding delays in financial reporting and actual impairment charges resulted in further declines in stock price, with a reported loss from operations of $112.3 million for Q3 2025, including $77.4 million in non-cash impairment charges [1].

Core Viewpoint - A class action lawsuit has been filed against Inovio Pharmaceuticals, Inc. and certain officers for alleged violations of federal securities laws during the Class Period from October 10, 2023, to December 26, 2025, seeking damages for investors who acquired Inovio securities during this time [1] Company Overview - Inovio Pharmaceuticals is a biotechnology company focused on developing DNA medicines to treat diseases, including those associated with human papilloma virus (HPV) [1] - The company's lead product candidate is INO-3107, aimed at treating recurrent respiratory papillomatosis (RRP), a rare disease caused by HPV [1] Allegations and Misstatements - Defendants allegedly made materially false and misleading statements regarding Inovio's business and prospects, including: - Deficiencies in the manufacturing of the CELLECTRA device [1] - Unlikelihood of submitting the INO-3107 Biologics License Application (BLA) to the FDA by the second half of 2024 [1] - Insufficient information to justify eligibility for FDA accelerated approval or priority review [1] - Overstated regulatory and commercial prospects for INO-3107 [1] Stock Price Impact - Following the revelation of a manufacturing issue on August 8, 2024, Inovio's stock price fell by $0.27 per share, or 3.1%, closing at $8.44 on August 9, 2024 [1] - On December 29, 2025, after the FDA accepted the INO-3107 BLA on a standard review timeline, the stock price dropped by $0.56 per share, or 24.45%, closing at $1.73 [1]